drugset / Trial / NCT03126786
Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this trial is to evaluate the safety and efficacy of suprachoroidal CLS-TA used with intravitreal aflibercept in subjects with DME.
Timeline
- Start
- 2017-07-11
- Primary completion
- 2018-04-17
- Completion
- 2018-04-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Comparator | CLS-TA | Unknown | 4 mg | Subcutaneous |